Denali and Sanofi Partner to Advance Small Molecules That Might Treat ALS, Other Diseases
Denali Therapeutics and Sanofi have joined efforts to develop small molecule inhibitors of the RIPK1 enzyme, a new…
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Denali Therapeutics and Sanofi have joined efforts to develop small molecule inhibitors of the RIPK1 enzyme, a new…
SOD1 gene mutations can contribute differently to the degenerative process of nerve cells involved in the progression of amyotrophic…
Canadian authorities have approved the sale of Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS). The therapy will…
The U.S. Food and Drug Administration has given positive feedback to MediciNova’s Phase 3 developmental plan for its investigational…
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are caused by different patterns of inflammation in the brain, which…
Amyotrophic lateral sclerosis’ toll on the thinking abilities and behavior of patients is as progressive and damaging as the disease’s physical…
Survival and quality of life of patients with more advanced amyotrophic lateral sclerosis (ALS) can be improved significantly with…
A diminished ability to regulate body temperature may be a manifestation of amyotrophic lateral sclerosis (ALS), results of a mice…
CannTrust is getting ready to launch a clinical trial to assess the effectiveness of its cannabidiol (CBD) oil…
Determining genetic profiles from patients’ blood samples can provide a broad view of the biological processes involved in amyotrophic…